Overview
Galux, a biotech company based in Seoul, South Korea, raised $29 million in Series B funding to develop AI-driven protein therapeutics. The funding round was led by Intervest and Dayli Partners, with participation from existing investors and new investors including Yuanta Investment and Korea Development Bank.
Products
Loading...
Recent Deals
Investors: Intervest, Dayli Partners, Yuanta Investment, Korea Development Bank
Galux, a biotech company based in Seoul, South Korea, raised $29 million in Series B funding to develop AI-driven protein therapeutics. The funding round was led by Intervest and Dayli Partners, with participation from existing investors and new investors including Yuanta Investment and Korea Development Bank.